卢元珺，博士，电子科技大学附属医院副研究员，主要研究方向为肝细胞癌的表观遗传学调控及耐药机制研究。

学术经历

2023/8-至今电子科技大学附属肿瘤医院

2016/9-2023/7香港大学

2009/9-2016/5中南大学

科研项目

参与香港研究资助局（RGC）基金项目（批准号17121419、17119621）、香港医疗卫生研究基金（HMRF）项目（批准号16172751）。

代表性学术成果

1.Yuanjun Lu#, Yazhou Liu#, Junjie Lan, Yau-Tuen Chan, Zixin Feng, Lan Huang, Ning Wang*, Weidong Pan*, Yibin Feng*. Thioredoxin-interacting protein-activated intracellular potassium deprivation mediates the anti-tumour effect of a novel histone acetylation inhibitor HL23, a fangchinoline derivative, in human hepatocellular carcinoma[J].Journal of Advanced Research, 2023, 51: 181-196. (IF=12.822)

2.Yuanjun Lu, Yau-Tuen Chan, Hor-Yue Tan, Cheng Zhang, Wei Guo, Yu Xu, Rakesh Sharma, Zhe-Sheng Chen, Yi-Chao Zheng, Ning Wang*, Yibin Feng*. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma[J].Journal of Experimental & Clinical Cancer Research, 2022, 41(1): 1-17. (IF=12.658)

3.Yuanjun Lu, Yau-Tuen Chan, Hor-Yue Tan, Sha Li, Ning Wang*, Yibin Feng*. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy[J].Molecular cancer, 2020, 19: 1-16. (IF=41.444)

4.Yuanjun Lu,Hor-Yue Tan, Ning Wang*, Yibin Feng*.Polarization of Tumor-Associated Macrophages by Chinese Medicine Intervention: Mechanisms and Applications[M]//Macrophage Activation-Biology and Disease.IntechOpen, 2019.

5.Yau-Tuen Chan,Yuanjun Lu, Junyu Wu, Cheng Zhang, Hor-Yue Tan, Zhaoxiang Bian, Ning Wang*, Yibin Feng*. CRISPR-Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives[J].Theranostics, 2022, 12(7): 3329. (IF=11.600)

6.Ning Wang, Hor-Yue Tan,Yuanjun Lu, Yau-Tuen Chan, Di Wang, Wei Guo, Yu Xu, Cheng Zhang, Feiyu Chen, Guoyi Tang, Yibin Feng*. PIWIL1 governs the crosstalk of cancer cell metabolism and immunosuppressive microenvironment in hepatocellular carcinoma[J].Signal Transduction and Targeted Therapy, 2021, 6(1): 86.(IF= 38.126)